Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis

Lemay A, André Lemay, A. Lemay, Rodolphe Maheux, Maheux R, R Maheux, Céline Huot, Huot C, C Huot, Blanchet J, J Blanchet, Jean Paul Blanchet, N Faure, Nacia Faure, Faure N
American journal of obstetrics and gynecology · 1988 · vol. 158(2) , pp. 233–236 · doi:10.1016/0002-9378(88)90128-7 · PMID:3124618 · W2070069876
article OA: closed CC0 ⤵ 37 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

This study evaluated the effectiveness of intranasal and subcutaneous luteinizing hormone-releasing hormone agonist administration in suppressing ovarian function for endometriosis treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

We have previously reported reversible hypogonadism induced by the intranasal administration of the luteinizing hormone-releasing hormone agonist buserelin as a new therapeutic approach for endometriosis. Thirteen patients were randomized to receive intranasal buserelin (400 micrograms 3 times a day) or subcutaneous buserelin injection (200 micrograms once daily) for a 6- to 9-month period. Both routes of administration were effective in inhibiting serum estradiol levels to near the menopausal range after 1 month of treatment. The two dosage regimens had also a comparable efficacy in alleviating endometriosis symptoms and in reducing the revised American Fertility Society scoring at laparoscopic examination. The implant score mainly decreased by more than 70%. The occurrence of side effects was similar in both groups, and side effects were mainly hot flushes, dyspareunia secondary to decreased vaginal secretion, and decreased libido. Results of hemogram, urinalysis, and serum biochemical and hormonal tests remained in the normal range. The ovulatory cycle rapidly returned after the cessation of treatment, and three pregnancies occurred in six previously infertile patients. Intranasal and subcutaneous buserelin were well accepted and equally effective in inhibiting the pituitary-ovarian function, which caused mild menopausal symptoms but an important regression of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Ovary Pelvic Neoplasms Administration, Intranasal Adult Buserelin Buserelin Endometriosis Estradiol Estradiol Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Injections, Subcutaneous Luteinizing Hormone Luteinizing Hormone Ovary Pelvic Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (9)

Cited by (36)

Source provenance

europepmc
last seen: 2026-08-26T06:08:41.316361+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:25.758913+00:00
unpaywall
last seen: 2026-08-26T06:23:03.089193+00:00
License: CC0 · commercial use OK